Structure Therapeutics
GPCR
196 hedge funds and large institutions have $3.22B invested in Structure Therapeutics in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 58 reducing their positions, and 39 closing their positions.
45% more call options, than puts
Call options by funds: $27.4M | Put options by funds: $18.9M
26% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 58
0% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 39
1% less funds holding
Funds holding: 197 → 196 (-1)
14.16% less ownership
Funds ownership: 108.4% → 94.24% (-14%)
30% less capital invested
Capital invested by funds: $4.58B → $3.22B (-$1.36B)
63% less funds holding in top 10
Funds holding in top 10: 16 → 6 (-10)
Top Buyers
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$63.7M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$37.3M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$32.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.6M |
| 5 |
O
OrbiMed
New York
|
+$21.5M |
Top Sellers
GPCR Hedge Fund Activity: Q1 2026 in Review
196 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q1 2026, worth a combined $3.22B — down 30% from $4.58B a quarter earlier.
Fund positioning in GPCR was balanced in Q1 2026: 39 funds opened new positions, 39 closed out, 73 added to existing stakes and 58 trimmed.
The largest buyer was American Century Companies, adding an estimated $63.7M. The largest seller was TCG Crossover Management, cutting an estimated $53.4M.
- 196 institutional investors held Structure Therapeutics (GPCR) as of Q1 2026, down from 197 in Q4 2025.
- Funds reported $3.22B of Structure Therapeutics stock for Q1 2026, down 30% quarter-over-quarter.
- 39 funds opened new Structure Therapeutics positions in Q1 2026 and 39 closed out, a net change of 0 holders.
- The largest Structure Therapeutics buyer in Q1 2026 was American Century Companies, an estimated $63.7M added.
- The largest Structure Therapeutics seller in Q1 2026 was TCG Crossover Management, an estimated $53.4M sold.
Based on aggregated 13F filings for Q1 2026.